Pemetrexed for Injection, USP Brand Name Equivalent: Alimta Pemetrexed for Injection, USP 100 mg per vial Unit of Sale NDC 71288-166-10 Unit of Use NDC 71288-166-10 Container Type SD Glass Vial Strength 100 mg per vial Concentration N/A Fill Volume N/A Vial Size 10 mL Closure 20 mm Units of Sale 1 Pack (1 X 1) Minimum Order 1 Case (108 X 1) Product Information Preservative Free Not made with natural rubber latex AP Rated Pemetrexed for Injection, USP 500 mg per vial Unit of Sale NDC 71288-167-50 Unit of Use NDC 71288-167-50 Container Type SD Glass Vial Strength 500 mg per vial Concentration N/A Fill Volume N/A Vial Size 50 mL Closure 20 mm Units of Sale 1 Pack (1 X 1) Minimum Order 1 Case (108 X 1) Product Information Preservative Free Not made with natural rubber latex AP Rated Pemetrexed for Injection, USP 750 mg per vial Unit of Sale NDC 71288-147-50 Unit of Use NDC 71288-147-50 Container Type SD Glass Vial Strength 750 mg per vial Concentration N/A Fill Volume N/A Vial Size 50 mL Closure 20 mm Units of Sale 1 Pack (1 X 1) Minimum Order 1 Pack (1 X 1) Product Information Preservative Free Not made with natural rubber latex AP Rated Pemetrexed for Injection, USP 1 g per vial Unit of Sale NDC 71288-148-51 Unit of Use NDC 71288-148-51 Container Type SD Glass Vial Strength 1 g per vial Concentration N/A Fill Volume N/A Vial Size 100 mL Closure 20 mm Units of Sale 1 Pack (1 X 1) Minimum Order 1 Pack (1 X 1) Product Information Preservative Free Not made with natural rubber latex AP Rated The brands mentioned here are the trademarks of their respective owners
As an IgG, the antibody has two main functional domains
Remarkably, at this higher dose (240 g three times a day), the mean reduction in body weight with pramlintide treatment over 16 weeks was approximately twice that previously observed over a similar time-frame in insulin-treated subjects with type 2 diabetes who were treated with lower pramlintide doses (120 g)
The diagnostic process typically involves: Clinical history taking, focusing on symptoms (fatigue, neurological changes, dietary habits) Physical examination for signs of anaemia or neurological impairment Blood tests including full blood count, serum B12, and often folate levels Additional investigations such as intrinsic factor antibodies or parietal cell antibodies if pernicious anaemia is suspected For borderline results, additional tests like holotranscobalamin (active B12) may be considered NICE guidance recommends that treatment should commence based on clinical presentation if neurological symptoms are present, without waiting for laboratory confirmation, as delays can result in irreversible nerve damage
Week-by-Week Expectations on AOD-9604 Honest expectations matter
